ESMO 2023 | The future of gastric cancer treatment beyond ESMO 2023

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the future of gastric cancer treatment, highlighting the need for a target beyond HER2 considering the current standard of care. Efforts should be made to improve outcomes for patients who are PD-1 low and therefore not suitable for immunotherapies. MET and EGFR targeted therapies are showing preliminary efficacy and emerging biomarkers such as lysyl-tRNA Synthetase (KRS) and Claudin18.2 are promising. Transcriptome analyses are being conducted to assess the use of antibody-drug conjugates (ADCs); despite difficulties, the outlook is still bright for the future of gastric cancer treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.